|11.84||+0.0300||+0.25%||Vol 260.52K||1Y Perf 51.22%|
|Oct 3rd, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||36.00||Analyst Rating||Strong Buy 1.29|
|Potential %||204.05||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★★ 54.68|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★★★★+ 60.60|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||26.42||Earnings Rating||—|
|Market Cap||497.91M||Earnings Date||14th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||14th Nov 2023|
|Estimated EPS Next Report||-0.67|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||398.55K|
|Avg. Monthly Volume||378.07K|
|Avg. Quarterly Volume||277.75K|
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) stock closed at 11.81 per share at the end of the most recent trading day (a -7.23% change compared to the prior day closing price) with a volume of 335.38K shares and market capitalization of 497.90M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 78 people. 4D Molecular Therapeutics Inc. CEO is David Kirn.
The one-year performance of 4D Molecular Therapeutics Inc. stock is 51.22%, while year-to-date (YTD) performance is -46.83%. FDMT stock has a five-year performance of %. Its 52-week range is between 6.58 and 26.49, which gives FDMT stock a 52-week price range ratio of 26.42%
4D Molecular Therapeutics Inc. currently has a PE ratio of -7.00, a price-to-book (PB) ratio of 2.99, a price-to-sale (PS) ratio of 358.52, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -40.40%, a ROC of -41.72% and a ROE of -44.24%. The company’s profit margin is -%, its EBITDA margin is -5 208.40%, and its revenue ttm is $1.88 Million , which makes it $0.06 revenue per share.
Of the last four earnings reports from 4D Molecular Therapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. 4D Molecular Therapeutics Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for 4D Molecular Therapeutics Inc. is Strong Buy (1.29), with a target price of $36, which is +204.05% compared to the current price. The earnings rating for 4D Molecular Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
4D Molecular Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
4D Molecular Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 68.23, ATR14 : 0.74, CCI20 : -151.83, Chaikin Money Flow : -0.37, MACD : -1.10, Money Flow Index : 0.00, ROC : -25.11, RSI : 13.88, STOCH (14,3) : 5.51, STOCH RSI : 0.00, UO : 29.71, Williams %R : -94.49), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of 4D Molecular Therapeutics Inc. in the last 12-months were: August J. Moretti (Option Excercise at a value of $28 230), Bizily Scott (Option Exercise at a value of $30 150), Bizily Scott (Sold 3 750 shares of value $78 188 ), Chacko Jacob (Sold 0 shares of value $-47 050 ), David Kirn (Sold 227 724 shares of value $5 139 036 ), Global Investors LP. Viking (Buy at a value of $13 600 000), Jacob M. Chacko (Option Excercise at a value of $47 050), Jacob M. Chacko (Sold 5 000 shares of value $100 270 ), Kirn David (Sold 53 970 shares of value $1 102 230 ), Moretti August (Sold 0 shares of value $-28 230 ), Scott Bizily (Option Excercise at a value of $169 275), Scott Bizily (Sold 23 493 shares of value $481 773 )
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.